Skip to main content
. 2022 Mar 30;66(6):661–670. doi: 10.1165/rcmb.2021-0305OC

Figure 5.

Figure 5.

ORMDL3 regulates the cell viability of 16HBE cells. (A) The relative fold change of lactate dehydrogenase (LDH) release in ORMDL3-overexpressing (ORMDL3) cells compared with Ctrl 16HBE lines in the presence or absence of SERCA activator CDN1163 (1 μM) for 16 hours. Means ± SD were from three biological repeats with six technical repeats for each group. (B) The relative fold change of LDH in ORMDL3-deficient (KO) and WT 16HBE cells in the presence or absence of SERCA2 inhibitors CPA (20 μM) or Tg (20 nM) for 16 hours. Means ± SD were from two biological repeats, six technical repeats for each group. *P < 0.05. One-way ANOVA followed by unpaired t test was used for statistical analysis. (C) Apoptosis markers including cleaved Caspase 3 and cleaved PARP were detected in 16HBE cells with various treatments or transfections. Lanes 1 and 4 are from cells treated with etoposide (ETO, 10 μM, 24 h) and TRAIL (100 nM, 6 h), respectively, two inducers of apoptosis, as positive controls. Lanes 2 and 3 are control and ORMDL3-overexpressing lines, respectively. Two independent experiments were performed.